Population pharmacokinetics as a method to detect variable risperidone exposure in patients suffering from dementia with behavioral disturbances

Robert Bies, Benoit H. Mulsant, Jules Rosen, Kimberly A. Huber, Nicole L. Wilson, Margaret A. Kirshner, Bruce G. Pollock

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objective: This study was intended to compare the consistency of risperidone exposure in patients who have dementia and behavioral disturbances treated in a psychiatric hospital versus a community care setting. Methods: Population pharmacokinetic modeling was used to assess the consistency of risperidone exposure in Alzheimer's disease patients with agitation. The ratio of predicted to observed drug concentrations (Cpred/Cobs) derived from this model was used to compare exposure in the inpatient versus long-term/home care settings using both the mean and the variance of this term across groups. Results: The modeled Cpred/Cobs ratios had a much higher within-subject variance in the inpatients than in the community care patients (117.03% vs 72.35%; P <0.001). The central tendencies of the Cpred/Cobs ratios across the 2 groups were not significantly different. Conclusions: Exposure to risperidone was more variable in a psychiatric hospital than in a community care setting. Future research may help to identify the specific contributors to the increased variance observed in this pilot study.

Original languageEnglish (US)
Pages (from-to)87-91
Number of pages5
JournalAmerican Journal Geriatric Pharmacotherapy
Volume3
Issue number2
DOIs
StatePublished - Jun 2005
Externally publishedYes

Fingerprint

Risperidone
Dementia
Pharmacokinetics
Psychiatric Hospitals
Inpatients
Population
Long-Term Care
Home Care Services
Patient Care
Alzheimer Disease
Pharmaceutical Preparations

Keywords

  • Alzheimer's disease
  • Geriatric psychiatry
  • Population pharmacokinetics
  • Risperidone

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Geriatrics and Gerontology

Cite this

Population pharmacokinetics as a method to detect variable risperidone exposure in patients suffering from dementia with behavioral disturbances. / Bies, Robert; Mulsant, Benoit H.; Rosen, Jules; Huber, Kimberly A.; Wilson, Nicole L.; Kirshner, Margaret A.; Pollock, Bruce G.

In: American Journal Geriatric Pharmacotherapy, Vol. 3, No. 2, 06.2005, p. 87-91.

Research output: Contribution to journalArticle

Bies, Robert ; Mulsant, Benoit H. ; Rosen, Jules ; Huber, Kimberly A. ; Wilson, Nicole L. ; Kirshner, Margaret A. ; Pollock, Bruce G. / Population pharmacokinetics as a method to detect variable risperidone exposure in patients suffering from dementia with behavioral disturbances. In: American Journal Geriatric Pharmacotherapy. 2005 ; Vol. 3, No. 2. pp. 87-91.
@article{f08481c6c1e64b2d809f609c9cc6a0f3,
title = "Population pharmacokinetics as a method to detect variable risperidone exposure in patients suffering from dementia with behavioral disturbances",
abstract = "Objective: This study was intended to compare the consistency of risperidone exposure in patients who have dementia and behavioral disturbances treated in a psychiatric hospital versus a community care setting. Methods: Population pharmacokinetic modeling was used to assess the consistency of risperidone exposure in Alzheimer's disease patients with agitation. The ratio of predicted to observed drug concentrations (Cpred/Cobs) derived from this model was used to compare exposure in the inpatient versus long-term/home care settings using both the mean and the variance of this term across groups. Results: The modeled Cpred/Cobs ratios had a much higher within-subject variance in the inpatients than in the community care patients (117.03{\%} vs 72.35{\%}; P <0.001). The central tendencies of the Cpred/Cobs ratios across the 2 groups were not significantly different. Conclusions: Exposure to risperidone was more variable in a psychiatric hospital than in a community care setting. Future research may help to identify the specific contributors to the increased variance observed in this pilot study.",
keywords = "Alzheimer's disease, Geriatric psychiatry, Population pharmacokinetics, Risperidone",
author = "Robert Bies and Mulsant, {Benoit H.} and Jules Rosen and Huber, {Kimberly A.} and Wilson, {Nicole L.} and Kirshner, {Margaret A.} and Pollock, {Bruce G.}",
year = "2005",
month = "6",
doi = "10.1016/j.amjopharm.2005.07.002",
language = "English (US)",
volume = "3",
pages = "87--91",
journal = "American Journal Geriatric Pharmacotherapy",
issn = "1543-5946",
publisher = "Excerpta Medica",
number = "2",

}

TY - JOUR

T1 - Population pharmacokinetics as a method to detect variable risperidone exposure in patients suffering from dementia with behavioral disturbances

AU - Bies, Robert

AU - Mulsant, Benoit H.

AU - Rosen, Jules

AU - Huber, Kimberly A.

AU - Wilson, Nicole L.

AU - Kirshner, Margaret A.

AU - Pollock, Bruce G.

PY - 2005/6

Y1 - 2005/6

N2 - Objective: This study was intended to compare the consistency of risperidone exposure in patients who have dementia and behavioral disturbances treated in a psychiatric hospital versus a community care setting. Methods: Population pharmacokinetic modeling was used to assess the consistency of risperidone exposure in Alzheimer's disease patients with agitation. The ratio of predicted to observed drug concentrations (Cpred/Cobs) derived from this model was used to compare exposure in the inpatient versus long-term/home care settings using both the mean and the variance of this term across groups. Results: The modeled Cpred/Cobs ratios had a much higher within-subject variance in the inpatients than in the community care patients (117.03% vs 72.35%; P <0.001). The central tendencies of the Cpred/Cobs ratios across the 2 groups were not significantly different. Conclusions: Exposure to risperidone was more variable in a psychiatric hospital than in a community care setting. Future research may help to identify the specific contributors to the increased variance observed in this pilot study.

AB - Objective: This study was intended to compare the consistency of risperidone exposure in patients who have dementia and behavioral disturbances treated in a psychiatric hospital versus a community care setting. Methods: Population pharmacokinetic modeling was used to assess the consistency of risperidone exposure in Alzheimer's disease patients with agitation. The ratio of predicted to observed drug concentrations (Cpred/Cobs) derived from this model was used to compare exposure in the inpatient versus long-term/home care settings using both the mean and the variance of this term across groups. Results: The modeled Cpred/Cobs ratios had a much higher within-subject variance in the inpatients than in the community care patients (117.03% vs 72.35%; P <0.001). The central tendencies of the Cpred/Cobs ratios across the 2 groups were not significantly different. Conclusions: Exposure to risperidone was more variable in a psychiatric hospital than in a community care setting. Future research may help to identify the specific contributors to the increased variance observed in this pilot study.

KW - Alzheimer's disease

KW - Geriatric psychiatry

KW - Population pharmacokinetics

KW - Risperidone

UR - http://www.scopus.com/inward/record.url?scp=23944446777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23944446777&partnerID=8YFLogxK

U2 - 10.1016/j.amjopharm.2005.07.002

DO - 10.1016/j.amjopharm.2005.07.002

M3 - Article

C2 - 16129385

AN - SCOPUS:23944446777

VL - 3

SP - 87

EP - 91

JO - American Journal Geriatric Pharmacotherapy

JF - American Journal Geriatric Pharmacotherapy

SN - 1543-5946

IS - 2

ER -